Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine
PMCID: PMC12173229
PMID: 40526688
DOI: 10.1371/journal.pone.0326029
Journal: PloS one
Publication Date: 2025-6-17
Authors: Shaykevich A, Chae D, Silverman I, Goel S, Maitra R
Key Points
- Carbamazepine and oncolytic reovirus demonstrate synergistic effects in inducing autophagy in KRAS-mutated colorectal cancer cells
- Dual treatment significantly increased autophagy-related protein expression (p < 0.001 for multiple proteins at 6h and 24h)
- Combination therapy offers a targeted approach for KRAS-mutated colorectal cancer with enhanced autophagic cell death
Summary
This preclinical study investigated a novel combination therapy for colorectal cancer patients with KRAS mutations, exploring the synergistic potential of oncolytic reovirus and carbamazepine in enhancing autophagy-mediated cancer cell death. The research focused on how these agents interact specifically in KRAS-mutated cell lines, demonstrating that the dual treatment significantly increases autophagy-related protein expression and autophagosome formation compared to individual treatments.
The study revealed that the combination of carbamazepine and reovirus preferentially targets KRAS-mutated colorectal cancer cells by dramatically upregulating key autophagy proteins and genes. Transmission electron microscopy confirmed increased autophagosome formation, with the dual treatment showing a synergistic effect that was more pronounced in KRAS-mutant cells compared to wild-type cells. These findings suggest a promising therapeutic approach that could potentially improve treatment outcomes for patients with KRAS-mutated colorectal cancer.